Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Prospect Venture Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
5,636,351Website Global Rank
1,670Website Monthly Traffic
Twitter Followers
Description
Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2009 | DFine | Venture Round | 0 |
| 1/2010 | DFine | Venture Round | 0 |
| 11/2011 | DFine | Venture Round | 25M |
| 6/2003 | Opus Medical | Series C | 13.6M |
| 6/2007 | Roxro Pharma | Series B | 42.7M |
| 10/2005 | Roxro Pharma | Series B | 21.6M |
| 3/2002 | Signature BioScience | Series E | 0 |
| 8/2009 | Gloucester Pharmaceuticals | Series D | 29M |
| 8/2002 | Archemix | Series A | 51.8M |
| 1/2011 | SurePoint Medical | Venture Round | - |
| 4/2007 | Aspen MedTech | Venture Round | 1M |
| 11/2005 | Nanosys | Series C | 0 |
| 3/2008 | SurgRx | Series G | 19.8M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 6/2004 | Rejuvenon | Series B | 37M |
| 8/2010 | Complete Genomics | Series E | 39M |
| 7/2010 | DFine | Venture Round | 36.2M |
| 6/2012 | SentreHEART | Series C | 26M |
| 11/2011 | NGM Biopharmaceuticals | Series B | 55.4M |
| 9/2004 | SurgRx | Series D | 11.9M |
| 4/2007 | SurgRx | Series F | 20M |
| 9/2008 | Baxano | Series B | 20M |
| 7/2007 | Neomend | Series C | 6M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 3/2004 | Phylogix Inc. | Series B | 12M |
| 1/2009 | Satori Pharmaceuticals | Series A | 22M |
| 10/2010 | NinePoint Medical | Series A | 33M |
| 1/2010 | Neomend | Series D | 30M |
| 10/2010 | Pathwork Diagnostics | Series C | 30M |
| 4/2004 | Archemix | Series B | 50M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 2/2002 | Nanosys | Series A | 15M |
| 6/2010 | Baxano | Series C | 30M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 10/2009 | Lux Biosciences | Series B | 50M |
| 8/2009 | Complete Genomics | Series D | 45M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 7/2003 | Tercica | Series B | 44M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 4/2003 | Nanosys | Series B | 0 |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 3/2015 | NGM Biopharmaceuticals | Series D | 57.5M |
| 1/2011 | Satori Pharmaceuticals | Series B | 7M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 4/2008 | Transave | Series D | 35M |
| 7/2013 | NGM Biopharmaceuticals | Series C | 50M |
| 5/2006 | Cogentus Pharmaceuticals | Series A | - |
| 9/2016 | SentreHEART | Series D | 35M |
| 9/2006 | Alvine Pharmaceuticals | Series A | 8M |
| 10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
| 12/2007 | Cogentus Pharmaceuticals | Series C | 62.5M |
| 2/2002 | Metreo | Series C | 15M |
| 5/2009 | Visiogen | Series D | 40M |
| 11/2005 | Hansen Medical | Venture Round | - |
| 4/2005 | Allux Medical | Series B | 5M |
| 7/2005 | Vitae Pharmaceuticals | Series C | 15M |
| 4/2008 | DFine | Series D | 20M |
| 12/2005 | DFine | Series B | 6.5M |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 12/2009 | NGM Biopharmaceuticals | Series A | 26.6M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 10/2004 | Gloucester Pharmaceuticals | Series B | 29M |
| 4/2007 | Cogentus Pharmaceuticals | Series B | 15M |
| 11/2007 | Vitae Pharmaceuticals | Series D | 15M |
| 3/2014 | Element Science | Series A | 12.5M |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 15M |
| 10/2011 | Azelon Pharmaceuticals | Series A | 4.5M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 10/2011 | Topica Pharmaceuticals | Series B | 27M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 1/2004 | Vitae Pharmaceuticals | Series B | 15M |
| 9/2004 | Allux Medical | Series A | 800k |
| 5/2005 | AVEO Oncology | Series C | 5M |
| 2/2007 | Visiogen | Venture Round | 24M |
| 8/2002 | Biospect | Series A | 4M |
| 3/2014 | NinePoint Medical | Series B | 34M |
| 9/2016 | SentreHEART | Series D | 0 |
| 3/2015 | NGM Biopharmaceuticals | Series D | 0 |
| 4/2014 | Nora Therapeutics | Series B | 0 |
| 3/2014 | Element Science | Series A | 0 |
| 3/2014 | NinePoint Medical | Series B | 0 |
| 7/2013 | NGM Biopharmaceuticals | Series C | 0 |
| 6/2012 | SentreHEART | Series C | 0 |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 0 |
| 11/2011 | DFine | Venture Round | 0 |
| 11/2011 | NGM Biopharmaceuticals | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
